Downloaded by [New York University] at 02:09 15 August 2016 Alzheimer’S Disease and Other Dementias

Total Page:16

File Type:pdf, Size:1020Kb

Downloaded by [New York University] at 02:09 15 August 2016 Alzheimer’S Disease and Other Dementias Downloaded by [New York University] at 02:09 15 August 2016 Alzheimer’s Disease and Other Dementias Working with the needs of patients with Alzheimer’s disease can be a major challenge for primary care physicians, psychiatrists, and other mental health professionals. Alzheimer’s wreaks havoc on the patient, and its degenerative nature can create a protracted period of anguish and anxiety for the patient’s family. Dr. Marc Agronin has put his years of experience as a geriatric psychiatrist to work to create an eminently useful resource for psychiatrists and others who treat patients suffering from Alzheimer’s disease or other dementias. Now in its third edition, Alzheimer’s Disease and Other Dementias uses con- cise and clear language to outline the symptoms, effects, and treatments used to combat the progress of Alzheimer’s disease and other dementias likely to be suffered by older patients. Enriched by case studies from his own clinical practice, Dr. Agronin creates a volume full of humanity, insight, and knowledge that is sure to inform and improve the habits and methods of any clinician who deals with Alzheimer’s disease and other forms of dementia. Marc E. Agronin , MD, is a board-certified adult and geriatric psychiatrist; he serves as the medical director for mental health and clinical research at the Miami Jewish Health Systems and as an affiliate associate professor of psychiatry and neurology at the University of Miami Miller School of Medicine. He is the author of numerous articles and books in the field of psychiatry and a nationally known speaker and expert on Alzheimer’s disease and other late-life psychiatric disorders. In 2008, Dr. Agronin was named “clinician of the year” by the American Association for Geriatric Psychiatry. He is the author of How We Age: A Doctor’s Journey into the Heart of Growing Old and Therapy with Older Clients: Key Strategies for Success , as well as coeditor of Principles and Practice of Geriatric Downloaded by [New York University] at 02:09 15 August 2016 Psychiatry, second edition. This page intentionally left blank Downloaded by [New York University] at 02:09 15 August 2016 Alzheimer’s Disease and Other Dementias A Practical Guide Third Edition Marc E. Agronin Downloaded by [New York University] at 02:09 15 August 2016 Third edition published 2014 by Routledge 711 Third Avenue, New York, NY 10017 and by Routledge 27 Church Road, Hove, East Sussex BN3 2FA Routledge is an imprint of the Taylor & Francis Group, an informa business © 2014 Marc E. Agronin The right of Marc E. Agronin to be identified as author of this work has been asserted by him in accordance with sections 77 and 78 of the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Trademark notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. First edition published by Lippincott Williams & Wilkins 2004 Second edition published by Lippincott Williams & Wilkins 2007 Library of Congress Cataloging-in-Publication Data Agronin, Marc E. Alzheimer’s disease and other dementias : a practical guide / by Marc E. Agronin. — 3rd edition. pages cm Includes bibliographical references and index. 1. Dementia—Handbooks, manuals, etc. 2. Dementia—Patients—Care— Handbooks, manuals, etc. 3. Caregivers—Handbooks, manuals, etc. 4. Geriatric psychiatry—Handbooks, manuals, etc. I. Title. RC521.A377 2014 616.8′3—dc23 2013037410 ISBN: 978-0-415-85699-7 (hbk) ISBN: 978-0-415-85700-0 (pbk) ISBN: 978-0-203-70836-1 (ebk) Typeset in Minion by Apex CoVantage, LLC Downloaded by [New York University] at 02:09 15 August 2016 To the past . The blessed memory of my grandparents, Dr. Simon and Eva Cherkasky and Tany and Etta Agronin; To the present . The love and support of my wife, Robin; To the future . My sons, Jacob, Max, and Samuel Downloaded by [New York University] at 02:09 15 August 2016 This page intentionally left blank Downloaded by [New York University] at 02:09 15 August 2016 Contents Foreword ix peter v. rabins Acknowledgments xi Introduction to the Third Edition xiii PART I Clinical Assessment of Dementia 1 1 An Overview of Dementia 3 2 The Dementia Workup 13 PART II Dementia Subtypes 39 3 Mild Cognitive Impairment 41 4 Alzheimer’s Disease 48 5 Vascular Dementia 83 Downloaded by [New York University] at 02:09 15 August 2016 6 Dementia with Lewy Bodies 96 7 Frontotemporal Dementia 105 8 Dementia Associated with Medical Conditions 119 viii Contents PART III Psychiatric Conditions Associated with Dementia 151 9 Agitation and Psychosis 153 10 Depression, Anxiety, and Apathy 183 PART IV Psychosocial Issues in Dementia Care 203 11 Legal and Ethical Issues 205 12 Caring for the Caregiver 217 Index 235 Downloaded by [New York University] at 02:09 15 August 2016 Foreword Physicians often ask themselves, Why should I be interested in brain diseases such as dementias? In this third edition of Alzheimer’s Disease and Other Dementias, A Practical Guide , Dr. Marc Agronin provides the answer. From the description of Alzheimer’s disease by psychiatrist Alois Alzheimer to the current methods of diagnosis and treat- ment, clinicians have much to learn about and much to contribute to the assessment and management of both patients with this group of illnesses and their daily caregivers. In a direct, readable fashion, Dr. Agronin nicely addresses many of the questions raised by patients, caregivers, and clinicians. He does not oversimplify things, and he does acknowledge that, at times, physicians cannot be as specific as they would like to be. This practical guide is just what the title suggests—useful, succinct, and accessible to the busy practitioner. Peter V. Rabins, MD, MPH Professor, Department of Psychiatry Johns Hopkins School of Medicine, Baltimore, Maryland Downloaded by [New York University] at 02:09 15 August 2016 This page intentionally left blank Downloaded by [New York University] at 02:09 15 August 2016 Acknowledgments First, I thank Anna Moore for giving me the opportunity to revise this book in a third edition, as well as for her guidance, enthusiasm, and confidence; I also thank the staff members at Routledge who have been involved in producing and promoting this book. My wife, Robin, provided the warmest environment imaginable in which to write and revise this book, as well as the love, support, and time to do so. My sons Jacob, Max, and Sam have always provided necessary distractions from my labors; my sincere hope is that one day they will pick up a copy of their father’s book on dementia and react quizzically to all the time and effort I spent writing about a disease that has been eradicated in their lifetimes. I also acknowledge the support of my parents, Ronald and Belle Agronin; my siblings, Robin and Greg Druckman and Michael and Ellen Agronin; and my in-laws, Fred and Marlene Lippman. I owe special thanks to Dr. Alan Cherkasky, whose practice of medicine has always inspired me and whose practical approach has always challenged me to translate even the most complicated approaches into practical benefits for the patient. Many colleagues at the Miami Jewish Health Systems (MJHS) have provided advice and have served as models of care for the book, including Dr. Mairelys Martinez, Niurka Colina, Dr. Amina Rivero, Jose Macias, Alex Gomez, Dr. Barbara Sparacino, and Dr. Brian Kiedrowski. I also acknowledge the inspiration of so many caregivers with whom I have worked, particularly the members of our caregiver support group, who embody the exemplary wisdom and dedication that is key to successful aging and coping. The most important inspiration for this book comes from memories of spending time seeing patients with my grandfather Dr. Simon Cherkasky, who practiced medicine in the small town of Kaukauna, Wisconsin, for over 50 years. He taught me many of the invaluable lessons that pervade this book—to work up each and every patient thor- Downloaded by [New York University] at 02:09 15 August 2016 oughly, to treat them completely, and to make medical decisions based on clinical need rather than on the availability of resources. This wisdom is crucial to the treatment of dementia. My grandmother Eva Cherkasky, his lifelong companion, provided from the warmth of her heart and her kitchen the true chicken soup for my soul. I hope that this book in a small way continues the educational and intellectual legacy of her own grand- father and my great-great grandfather, the beloved and well-respected teacher Rabbi Pesach Iser Gielczynski. This page intentionally left blank Downloaded by [New York University] at 02:09 15 August 2016 Introduction to the Third Edition Do not cast me off in old age; when my strength fails, do not forsake me. —Psalms 71:9 The diagnosis of dementia or even the possibility of such a diagnosis is often greeted with fear and trepidation by those affected. The ensuing fears of losing one’s mind and capa- bilities and of being abandoned or “put away” in an institution are contemplated as fates worse than death. The disease stealthily encroaches in some individuals, robbing them of insight into their illness before they can truly appreciate what has happened. Others notice the changes building month to month and year to year but resign themselves to the process. Still others fight the changes or those around them who insist that they cut back on the activities that once meant independence and integrity but now carry the risk of disaster.
Recommended publications
  • 2020 Question Book
    2020 QUESTION BOOK 13TH EDITION WHO WE ARE Welcome to the thirteenth edition of the Ninja’s Guide to PRITE! Loma Linda University Medical Center is located in sunny Southern California. about 60 miles east of Los Angeles. A part of the Adventist Health System, we provide patient care in one of the largest non-profit health systems in the nation. Loma Linda's mission is to excel in medical education, global healthcare, and community outreach, all under a central tenant: "To Make Man Whole." At the Loma Linda Department of Psychiatry, our residents are trained in many diverse patient care settings. As an official World Health Organization Collaboration Center, our department funds resident electives in Global Mental Health at locations around the world. Additionally, our residents can participate in national and international disaster relief on the LLU Behavioral Health Trauma Team. We were proud to welcome our first group of Child and Adolescent Psychiatry fellows in the Summer of 2019 and work collaboratively with 3 other residency programs within the region. Our residency didactic education is constantly evolving based upon resident feedback, and our residents have the opportunity to aid in course development. More than anything, our residency fosters an environment where residents and faculty treat each other like family. Our faculty are dedicated to resident education and professional development. We believe in "taking 'No' off the table", encouraging innovative change, and passionately supporting our residents to achieve anything they set their minds to. For over a decade our residents have volunteered their time to create The Ninja's Guide to PRITE at our Annual Ninja PRITE Workshop.
    [Show full text]
  • New Therapeutic Property of Dimebon As a Neuroprotective Agent
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2016, 23, 1-12 1 REVIEW ARTICLE New Therapeutic Property of Dimebon as a Neuroprotective Agent Aleksey Ustyugov1, Elena Shevtsova1, George E. Barreto2,3, Ghulam Md Ashraf 4, Sergey O. Bachurin1 and Gjumrakch Aliev1,5,6,* 1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severniy Proezd 1, Cher- nogolovka, 142432, Russia; 2Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Uni- versidad Javeriana, Bogotá D.C., Colombia; 3Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 4King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Ara- bia; 5GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San An- tonio, TX, 78229, USA; 6School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA Abstract: Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of “old” agents with prominent neuroprotective effects. In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain’s pathological processes using in vivo protei- A R T I C L E H I S T O R Y nopathy models. In the study, neurodegenerative pathology has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which Received: March 13, 2016 Revised: June 08, 2016 are involved in a number of neurological disorders. We have also presented our in vitro Accepted: July 24, 2016 model based on overexpression of an aberrant mutant form of transactive response DNA DOI: 10.2174/0929867323666160804 binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.
    [Show full text]
  • Downloads/Drugs/…/Guidances/UCM078932
    UCLA UCLA Previously Published Works Title Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Permalink https://escholarship.org/uc/item/7kq6p5tv Journal Scientific reports, 8(1) ISSN 2045-2322 Authors Tian, Jide Dang, Hoa Wallner, Martin et al. Publication Date 2018-11-08 DOI 10.1038/s41598-018-32733-3 Peer reviewed eScholarship.org Powered by the California Digital Library University of California www.nature.com/scientificreports OPEN Homotaurine, a safe blood-brain barrier permeable GABAA-R-specifc agonist, ameliorates disease in Received: 12 April 2018 Accepted: 11 September 2018 mouse models of multiple sclerosis Published: xx xx xxxx Jide Tian, Hoa Dang, Martin Wallner, Richard Olsen & Daniel L. Kaufman There is a need for treatments that can safely promote regulatory lymphocyte responses. T cells express GABA receptors (GABAA-Rs) and GABA administration can inhibit Th1-mediated processes such as type 1 diabetes and rheumatoid arthritis in mouse models. Whether GABAA-R agonists can also inhibit Th17-driven processes such as experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), is an open question. GABA does not pass through the blood-brain barrier (BBB) making it ill-suited to inhibit the spreading of autoreactivity within the CNS. Homotaurine is a BBB-permeable amino acid that antagonizes amyloid fbril formation and was found to be safe but inefective in long-term Alzheimer’s disease clinical trials. Homotaurine also acts as GABAA-R agonist with better pharmacokinetics than that of GABA. Working with both monophasic and relapsing-remitting mouse models of EAE, we show that oral administration of homotaurine can (1) enhance CD8+CD122+PD-1+ and CD4+Foxp3+ Treg, but not Breg, responses, (2) inhibit autoreactive Th17 and Th1 responses, and (3) efectively ameliorate ongoing disease.
    [Show full text]
  • Practice Guideline
    THE AMERICAN ASSOCIATION PSYCHIATRIC PRACTICE GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT WITH OF ALCOHOL PATIENTS USE DISORDER lcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and THE AMERICAN PSYCHIATRIC ASSOCIATION A 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD PRACTICE GUIDELINE receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD- FOR THE associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Pharmacological Treatment of Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individu- Patients With Alcohol Use Disorder als. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.
    [Show full text]
  • Taurine and Its Analogs in Neurological Disorders Focus On
    Redox Biology 24 (2019) 101223 Contents lists available at ScienceDirect Redox Biology journal homepage: www.elsevier.com/locate/redox Review article Taurine and its analogs in neurological disorders: Focus on therapeutic T potential and molecular mechanisms Md. Jakariaa, Shofiul Azama, Md. Ezazul Haquea, Song-Hee Joa, Md. Sahab Uddinb, In-Su Kima,c, ∗ Dong-Kug Choia,c, a Department of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea b Department of Pharmacy, Southeast University, Dhaka, Bangladesh c Department of Integrated Bioscience and Biotechnology, College of Biomedical and Health Sciences, and Research Institute of Inflammatory Diseases (RID), Konkuk University, Chungju, South Korea ARTICLE INFO ABSTRACT Keywords: Taurine is a sulfur-containing amino acid and known as semi-essential in mammals and is produced chiefly by Taurine the liver and kidney. It presents in different organs, including retina, brain, heart and placenta and demonstrates Analogs extensive physiological activities within the body. In the several disease models, it attenuates inflammation- and Therapeutic oxidative stress-mediated injuries. Taurine also modulates ER stress, Ca2+ homeostasis and neuronal activity at Molecular role the molecular level as part of its broader roles. Different cellular processes such as energy metabolism, gene Clinical study and Neurological disorders expression, osmosis and quality control of protein are regulated by taurine. In addition, taurine displays po- tential ameliorating effects against different neurological disorders such as neurodegenerative diseases, stroke, epilepsy and diabetic neuropathy and protects against injuries and toxicities of the nervous system. Several findings demonstrate its therapeutic role against neurodevelopmental disorders, including Angelman syndrome, Fragile X syndrome, sleep-wake disorders, neural tube defects and attention-deficit hyperactivity disorder.
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • The Road from Estrangement to Reconciliation
    The Road From Estrangement to Reconciliation The Road from Estrangement to Reconciliation 15 Week Program Participant Name: ___________________________________ Date: _____________________________________________ Twitter: https://twitter.com/#!/Gatehouse_The Facebook: https://www.facebook.com/TheGatehouseChildAbuseInvestigationSupportSite YouTube: https://www.youtube.com/user/GatehouseThe?feature= Instagram: @thegatehousetoronto 1 The Road From Estrangement to Reconciliation Contents WEEK ONE – The Road From Estrangement to Reconciliation ............................................................................. 4 Introduction ............................................................................................................................................................. 5 4 Possible Outcomes .............................................................................................................................................. 5 The Pain of Estrangement ..................................................................................................................................... 6 The Roots of Estrangement................................................................................................................................... 6 Embracing Paradox ................................................................................................................................................. 7 WEEK TWO: Building a Self: The Importance of Autonomy ................................................................................
    [Show full text]
  • Intergenerational Estrangement Between Older Parents And
    Every family: Intergenerational estrangement between older parents and their adult-children Kylie Beth Agllias BSW (Hons), UoN, AUST. A thesis submitted for the degree of Doctor of Philosophy (Social Work) University of Newcastle School of Humanities and Social Science May 2011 Declaration This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying subject to the provisions of the Copyright Act 1968. Signed:............................................................. Date:.................................................. i Acknowledgements A mind that is stretched to a new idea never returns to its original dimension (Oliver W. Holmes) Some suggest the proof of a good thesis is when the examiner knows the student learnt something. However, the main lessons are the ones witnessed by supervisors, family, and friends, the lessons most often excluded from the text. I would like to thank the following people who witnessed and supported my doctoral journey and the associated life lessons: To my doctoral supervisors, mentors and colleagues, Professor Mel Gray and Doctor Jill Gibbons, I cannot thank you enough for your encouragement, guidance, and faith. You ‘saw me’ well before I knew myself. To my wonderfully generous, loving, amusing, and busy family, James, Kara, Paige, and Tyson, I love you. You are my world.
    [Show full text]
  • Adult Child-Parent Relationships: Predicting Physical and Emotional Estrangement
    Adult Child-Parent Relationships: Predicting Physical and Emotional Estrangement Brianne Pragg Penn State University Abstract It is often assumed that the relationship between parents and children are involun- tary and stable throughout the life course. However, a growing literature on the estrangement of adult children from their parents finds that this is not always the case. The current study uses Waves I – IV of the National Longitudinal Study of Adolescent to Adult Health (Add Health) to examine the predictors of different dimensions of adult child-parent estrange- ment. Physical and emotional estrangement are rarely considered separately in quantitative studies, but this study will explore these dimensions of estrangement separately and con- sider whether the predictors vary between types of estrangement and by gender of both the children and the parents. Acknowledgements This research was supported by funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to the Population Research Institute at The Pennsylvania State University for Population Research Infrastructure (R24HD041025) and Family Demography Training (T-32HD007514). 1 It is often assumed that parents and their children have unconditionally supportive relationships throughout the life course. However, studies on intergenerational relationships have found that the relationships between parents and their adult children are not always positive (Blake 2017). A growing literature on parent-child estrangement has found that some relationships between adult parents and their children are physically and/or emotion- ally distant, and others are dissolved entirely (Blake 2017). Depending on the measure or typology of estrangement used, studies estimate that between four and 27 percent of adult children report having strained relationships or no contact with their parents, making it a fairly common occurance over the life course (Agllias 2017; Gilligan et al.
    [Show full text]
  • Clinical Review Huntington's Disease
    CLINICAL REVIEW For the full versions of these articles see bmj.com Huntington’s disease Marianne J U Novak,1 2 Sarah J Tabrizi1 3 1National Hospital for Neurology Huntington’s disease is a devastating inherited and Neurosurgery, London neurodegenerative disease characterised by progressive motor, WC1N 3BG cognitive, and psychiatric symptoms. Patients may present 2Wellcome Trust Centre for Neuroimaging, UCL Institute of with any of these symptoms, and familiarity with the pheno- Neurology, London WC1N 3BG type is therefore important. Chorea and loss of balance are 3Department of Neurodegenerative early symptoms that patients notice, although families often Disease, UCL Institute of Neurology notice cognitive or personality changes before this. Correspondence to: S Tabrizi [email protected] The disease occurs in all racial groups but is most common in people of northern European origin. Its prevalence in the Cite this as: BMJ 2010;340:c3109 Western hemisphere is 7-10/100 000.w1 The mean age of onset doi: 10.1136/bmj.c3109 of symptoms is 40 years, but juvenile onset (<20 years) and older onset (>70 years) forms are well recognised. The Hunt- ington’s Disease Association (HDA) has records of 6161 adults with symptomatic Huntington’s disease and 541 children with juvenile Huntington’s disease (in England and Wales) at the Fig 1 | Statistical parametric map showing grey matter volume loss in patient groups compared with controls. Pre-A and time of writing. This is a conservative estimate of prevalence pre-B are premanifest Huntington’s disease gene carriers with because it includes only those people in contact with the HDA, estimated time to clinical disease onset greater than and less and it suggests that the true prevalence of the disease is higher than 10.8 years, respectively.
    [Show full text]
  • Sibling Estrangements Experienced by Children in Out-Of-Home Care and Moving Towards Permanence
    Relative strangers: Sibling estrangements experienced by children in out-of-home care and moving towards permanence Key terms: sibling placements, out-of-home care, sibling contact, family estrangement, permanence, sibling reunions Abstract Loss of sibling relationships is a common experience across international jurisdictions for children entering public care. This is the case despite statutory guidance that emphasizes the need to place siblings together when in their best interests, and increasingly robust evidence of the protective nature of sibling relationships when children face adversity. Research on the experiences and outcomes of siblings in care has thus far focused predominantly on placement and contact patterns, particularly of siblings in care concurrently. This study extends this research by comprehensively mapping sibling networks both within and outside the care system and measuring sibling estrangement (living apart and lack of contact) over time. Drawing on administrative and case file data within the Children’s Hearings System in Scotland, the circumstances of 204 children and young people from 50 sibling networks were examined longitudinally. The study found very high rates of sibling estrangement with seven in 10 relationships between a child in out-of-home care and a sibling classified as estranged and half of all siblings classified as strangers (siblings having never lived together and no record of any communication or meetings between the child and sibling). Moreover, sibling estrangement increased significantly as children moved through the care system. We argue that continued effort is needed to improve the accuracy with which aspects of sibling relationships of children in care are recorded and measured in order to assess the longer-term impact of state interventions on children’s lives and the capacity of child welfare agencies to meet policy goals.
    [Show full text]